Zelda Therapeutics Ltd (ASX: ZLD has announced it has secured regulatory approval to conduct a clinical trial of its cannabis medicines with chronic insomnia patients in Australia.
The trial is expected to commence in the first quarter of next year and patient recruitment should begin shortly. A randomised, placebo controlled, cross over study design will be used, where patients are selected at random to be treated with Zelda’s medicinal cannabis formulation or a placebo. Preliminary results from the trial are expected by Q3 2018.
The medicinal cannabis formulations for the clinical trial won’t be made in Australia, but manufactured by the Netherlands’ Eurofins Sinensis. Details of the cannabinoid profile of the medications have not been disclosed at this point.
The trial will be undertaken by the University of Western Australia (UWA) Centre for Sleep Science (CSS), which
... read more at: https://www.hempgazette.com/news/medical-cannabis-insomnia-mb0469/